In particular, CTGF is dysregulated in many cancer types, including melanoma [38], breast and lung carcinoma [39, 40], promoting cancer initiation, progression and drug resistance and regulating key properties of the TME [39, 41]. Here, CCN2 is linked to lung carcinoma.